USRM (US Stem Cell) Total Equity: $-14.75 Mil (As of Dec. 2022)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Total Equity?

US Stem Cell USRM -99.00% 12 Total Equity is $-14.75 Mil as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's total equity for the quarter that ended in Dec. 2022 was $-14.75 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

US Stem Cell Total Equity Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Total Equity Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.88 -9.48 -11.58 -12.77 -14.75

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.77 -13.37 -13.86 -14.20 -14.75
USRM
12GF Score
US Stem Cell Inc USRM
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

US Stem Cell's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=0.068-14.813
=-14.75

US Stem Cell's Total Equity for the quarter that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=0.068-14.813
=-14.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-14.75 Mil mean?
US Stem Cell (USRM) has a Total Equity of $-14.75 Mil as of Dec. 2022. The total amount of equity as record on a company's balance sheet. View historical data for US Stem Cell and its competitors.
Is US Stem Cell's Total Equity too high?
US Stem Cell's current Total Equity is $-14.75 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Total Equity compare to NOVNQ and RGRX?
US Stem Cell's Total Equity of $-14.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for US Stem Cell and its competitors. US Stem Cell's current Total Equity is $-14.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Total Equity of $-14.75 Mil. The current Total Equity is $-14.75 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For US Stem Cell (USRM), the current Total Equity is $-14.75 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price